Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate pharmacokinetics and outcomes in pediatric and adolescent Crohn's disease
NL-OMON61038Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Red blood cell methotrexate polyglutamate levels and Drug survival of methotrexate monotherapy. Started Jul 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON61038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61038.